ABEO
Price
$6.97
Change
+$0.12 (+1.75%)
Updated
Sep 3, 11:00 AM (EDT)
Capitalization
351.26M
75 days until earnings call
GOSS
Price
$2.65
Change
+$0.06 (+2.32%)
Updated
Sep 3, 11:13 AM (EDT)
Capitalization
588.92M
64 days until earnings call
Interact to see
Advertisement

ABEO vs GOSS

Header iconABEO vs GOSS Comparison
Open Charts ABEO vs GOSSBanner chart's image
Abeona Therapeutics
Price$6.97
Change+$0.12 (+1.75%)
Volume$300
Capitalization351.26M
Gossamer Bio
Price$2.65
Change+$0.06 (+2.32%)
Volume$4K
Capitalization588.92M
ABEO vs GOSS Comparison Chart in %
Loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABEO vs. GOSS commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a Hold and GOSS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (ABEO: $6.85 vs. GOSS: $2.59)
Brand notoriety: ABEO and GOSS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 74% vs. GOSS: 255%
Market capitalization -- ABEO: $351.26M vs. GOSS: $588.92M
ABEO [@Biotechnology] is valued at $351.26M. GOSS’s [@Biotechnology] market capitalization is $588.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $102.81B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 1 FA rating(s) are green whileGOSS’s FA Score has 0 green FA rating(s).

  • ABEO’s FA Score: 1 green, 4 red.
  • GOSS’s FA Score: 0 green, 5 red.
According to our system of comparison, ABEO is a better buy in the long-term than GOSS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 3 TA indicator(s) are bullish while GOSS’s TA Score has 4 bullish TA indicator(s).

  • ABEO’s TA Score: 3 bullish, 5 bearish.
  • GOSS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, GOSS is a better buy in the short-term than ABEO.

Price Growth

ABEO (@Biotechnology) experienced а -3.66% price change this week, while GOSS (@Biotechnology) price change was +2.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.60%. For the same industry, the average monthly price growth was +16.37%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

ABEO is expected to report earnings on Nov 17, 2025.

GOSS is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GOSS($589M) has a higher market cap than ABEO($351M). GOSS YTD gains are higher at: 186.314 vs. ABEO (22.980). ABEO has higher annual earnings (EBITDA): 80M vs. GOSS (-128.6M). ABEO has more cash in the bank: 226M vs. GOSS (213M). ABEO has less debt than GOSS: ABEO (24.1M) vs GOSS (203M). GOSS has higher revenues than ABEO: GOSS (40.2M) vs ABEO (400K).
ABEOGOSSABEO / GOSS
Capitalization351M589M60%
EBITDA80M-128.6M-62%
Gain YTD22.980186.31412%
P/E Ratio10.70N/A-
Revenue400K40.2M1%
Total Cash226M213M106%
Total Debt24.1M203M12%
FUNDAMENTALS RATINGS
ABEO vs GOSS: Fundamental Ratings
ABEO
GOSS
OUTLOOK RATING
1..100
7421
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
20100
PRICE GROWTH RATING
1..100
4735
P/E GROWTH RATING
1..100
54100
SEASONALITY SCORE
1..100
1750

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GOSS's Valuation (56) in the Pharmaceuticals Major industry is in the same range as ABEO (81) in the Pharmaceuticals Generic industry. This means that GOSS’s stock grew similarly to ABEO’s over the last 12 months.

GOSS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that GOSS’s stock grew similarly to ABEO’s over the last 12 months.

ABEO's SMR Rating (20) in the Pharmaceuticals Generic industry is significantly better than the same rating for GOSS (100) in the Pharmaceuticals Major industry. This means that ABEO’s stock grew significantly faster than GOSS’s over the last 12 months.

GOSS's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as ABEO (47) in the Pharmaceuticals Generic industry. This means that GOSS’s stock grew similarly to ABEO’s over the last 12 months.

ABEO's P/E Growth Rating (54) in the Pharmaceuticals Generic industry is somewhat better than the same rating for GOSS (100) in the Pharmaceuticals Major industry. This means that ABEO’s stock grew somewhat faster than GOSS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEOGOSS
RSI
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 13 days ago
84%
Bullish Trend 1 day ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 7 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYSOX97.66N/A
N/A
Rydex S&P 500 A
NGISX17.95N/A
N/A
Nationwide BNY Mellon Dyn US Core I.S
PMYTX47.40N/A
N/A
Putnam Core Equity Fund R6
LHCVX19.85N/A
N/A
Lord Abbett Health Care R6
MSOAX39.53-0.28
-0.70%
NYLI WMC Enduring Capital Class A